Competition Law Could Be Key To Lower Prices For Combo Drugs In UK
Executive Summary
HTA body NICE is exploring whether competition law impacts pricing of combination drugs in UK.
You may also be interested in...
UK’s Competition Body Says Pharma Firms Can Work Together On Access To Combination Therapies
The UK’s Competition and Markets Authority will not prioritize the investigation of pharmaceutical companies that enter commercial negotiations with the aim of making combination therapies cost effective, a move that the ABPI says is an “international first”.
UK: NICE Hints At ’Significant Changes’ To Come
At a recent event in London, NICE, the health technology appraisal institute for England and Wales, hinted that it could be in for some big changes over the coming years.
Companies Reluctant To Put Combo Drugs Through NICE, UK Breast Cancer Charity Warns
Companies are delaying putting their combination products through NICE, the health technology appraisal institute for England and Wales, warns the UK charity Breast Cancer Now.